Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orticumab - Abcentra

Drug Profile

Orticumab - Abcentra

Alternative Names: 2D03; Anti-oxLDL; BI-204; MLDL-1278A; RG-7418

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioInvent International
  • Developer Abcentra; BioInvent International; Genentech
  • Class Anti-inflammatories; Antibodies; Antihyperlipidaemics; Antipsoriatics; Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; LDL receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis
  • No development reported Aortic valve stenosis; Atherosclerosis

Most Recent Events

  • 06 Apr 2024 Efficacy data from phase II trial in Psoriasis presented at 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Aortic-valve-stenosis in USA (Parenteral)
  • 28 Feb 2022 No recent reports of development identified for clinical-Phase-Unknown development in Atherosclerosis in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top